A randomized, multicenter, double blinded, phase IV study comparing the safety and efficacy of Pegasys [Peginterferon alfa-2a] 180 microg plus Copegus [ribavirin] 1000 or 1200 mg to the currently approved combination of Pegasys 180 microg plus Copegus 800 mg in interferon-naive patients with chronic hepatitis C genotype 1 virus infection co-infected with HIV-1

Trial Profile

A randomized, multicenter, double blinded, phase IV study comparing the safety and efficacy of Pegasys [Peginterferon alfa-2a] 180 microg plus Copegus [ribavirin] 1000 or 1200 mg to the currently approved combination of Pegasys 180 microg plus Copegus 800 mg in interferon-naive patients with chronic hepatitis C genotype 1 virus infection co-infected with HIV-1

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2012

At a glance

  • Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PARADIGM
  • Sponsors Roche
  • Most Recent Events

    • 14 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
    • 03 Feb 2010 Planned number of patients changed from 400 to 415 as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top